Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Since progesterone receptor (PgR) is normally induced by estrogen, breast cancer lacking estrogen receptor (ER) would also be expected to lack PgR. However, a small percentage of breast cancers are ER- yet PgR+. These tumors might possess an ER which is defective in estrogen binding but is still functional in stimulating estrogen-responsive genes such as PgR. We have now detected such a variant, lacking exon 5 of the hormone-binding domain, using complementary DNA amplified by the polymerase chain reaction. This variant was the predominate ER RNA expressed in three ER-/PgR+ tumors. Furthermore, the variant ER constitutively activates transcription of a normally estrogen-dependent gene construct in yeast cells. The variant ER could explain the expression of PgR in certain tumors and have therapeutic implications.

[1]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[2]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[3]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[4]  J. Mester,et al.  Oncogenes homologous to steroid receptors? , 1985, Nature.

[5]  K. Yamamoto,et al.  Steroid receptor regulated transcription of specific genes and gene networks. , 1985, Annual review of genetics.

[6]  P Argos,et al.  The chicken oestrogen receptor sequence: homology with v‐erbA and the human oestrogen and glucocorticoid receptors. , 1986, The EMBO journal.

[7]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[8]  Pierre Chambon,et al.  A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.

[9]  E. W. Jones,et al.  Protease B of Saccharomyces cerevisiae: isolation and regulation of the PRB1 structural gene. , 1987, Genetics.

[10]  R. Coombes,et al.  Characterization of estrogen receptor messenger RNA in human breast cancer. , 1987, Cancer research.

[11]  J. Henry,et al.  Measurement of oestrogen receptor mRNA levels in human breast tumours. , 1988, British Journal of Cancer.

[12]  P. Chambon,et al.  The human oestrogen receptor functions in yeast , 1988, Nature.

[13]  S. Lehrer,et al.  A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. , 1988, Molecular endocrinology.

[14]  W. McGuire,et al.  Review: Steroid Receptors, Cellular Kinetics, and Lymph Node Status as Prognostic Factors in Breast Cancer , 1988 .

[15]  P. Chambon,et al.  Genomic organization of the human oestrogen receptor gene. , 1988, The EMBO journal.

[16]  D. Yee,et al.  Identification of an alternate type I insulin-like growth factor receptor beta subunit mRNA transcript. , 1989, The Journal of biological chemistry.

[17]  L. Murphy,et al.  Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. , 1989, Molecular endocrinology.

[18]  S. Lehrer,et al.  Identification of a variant form of the human estrogen receptor with an amino acid replacement. , 1989, Nucleic acids research.

[19]  J. Flier,et al.  Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. , 1989, Molecular endocrinology.

[20]  B. O’Malley,et al.  Expression of functional chicken oviduct progesterone receptors in yeast (Saccharomyces cerevisiae). , 1989, The Journal of biological chemistry.

[21]  P. Chambon,et al.  The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.

[22]  W. McGuire,et al.  Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. , 1990, Journal of the National Cancer Institute.

[23]  M. Sluyser,et al.  Steroid/thyroid receptor-like proteins with oncogenic potential: a review. , 1990, Cancer research.